Axsome Thera (AXSM) Stock Price, Quote & News

Company Profile

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptak...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 332 3241

Fax: 212 320 0245

Website: www.axsome.com

Address:

One World Trade Center, 22nd Floor, New York, United States

just_another_guy Sep. 17 at 4:02 AM

$AXSM Rexulti and Auvelity search trend on google is converging (trailing 12 months screenshot attached). Major spike in auvelity for last 2 weeks is because of TV commercials launching. Expect prescriptions to pick up shortly!

1 · Reply

highnihilism Sep. 16 at 6:19 PM

IWM: Russell 2000 → $AXSM Axsome Therapeutics $TPC Tutor Perini $TDOC Teladoc Health $LIF Life360 $MVST Microvast

1 · Reply

JDR1983 Sep. 16 at 3:51 PM

$AXSM Added 100 shares.

0 · Reply

jlfromli Sep. 16 at 2:33 PM

$AXSM HT sold This is not good Back to $80S?

1 · Reply

pi22dv7 Sep. 16 at 2:21 PM

$AXSM 20 bucks in 2 weeks, Damn something is really wrong which we are not aware?

1 · Reply

cadbrad1 Sep. 16 at 2:17 PM

$AXSM Been in this for a few years. I’ve seen these kind of drops right before big news and then it rockets up. Hopefully history repeats!

1 · Reply

jozef56 Sep. 16 at 1:47 PM

$AXSM this weak dollar will kill economics on long term ....fed should decrease intrest as max as possible to stimulate investors

0 · Reply

DiligentInvesting Sep. 16 at 1:35 PM

$AXSM should make a drug for bipolarity and treat its stock price with it. Jeez.

0 · Reply

quickaspeter Sep. 16 at 1:27 PM

$AXSM Let’s go!

0 · Reply

Vakeshka Sep. 16 at 12:11 PM

$AXSM Cantor Fitzgerald reaffirms Buy rating with $153 PT.

2 · Reply

Axsome Therapeutics, Inc. (AXSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 27, 2025, 7:00 AM EDT - 20 days ago

Axsome Therapeutics to Participate in Upcoming Investor Conferences

Aug 5, 2025, 1:40 PM EDT - 6 weeks ago

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Aug 4, 2025, 2:50 PM EDT - 6 weeks ago

Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 7:00 AM EDT - 6 weeks ago

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 25, 2025, 1:46 PM EDT - 7 weeks ago

Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy

Jul 21, 2025, 7:30 AM EDT - 2 months ago

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Jul 9, 2025, 7:00 AM EDT - 2 months ago

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

Jul 7, 2025, 7:00 AM EDT - 2 months ago

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

Jun 20, 2025, 7:00 AM EDT - 3 months ago

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

Jun 11, 2025, 7:00 AM EDT - 3 months ago

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

May 27, 2025, 7:00 AM EDT - 4 months ago

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

May 13, 2025, 7:00 AM EDT - 4 months ago

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

May 6, 2025, 12:48 PM EDT - 4 months ago

Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns

May 5, 2025, 11:44 AM EDT - 4 months ago

Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript

May 5, 2025, 10:41 AM EDT - 4 months ago

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

May 5, 2025, 7:00 AM EDT - 4 months ago

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 7:00 AM EDT - 4 months ago

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

Apr 8, 2025, 7:00 AM EDT - 5 months ago

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

Apr 4, 2025, 7:00 AM EDT - 5 months ago

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

Apr 1, 2025, 7:18 AM EDT - 6 months ago

Axsome's depression treatment fails to meet main goal of late-stage study

Mar 25, 2025, 7:13 AM EDT - 6 months ago

Axsome Therapeutics' ADHD drug meets main goal in late-stage study

Mar 21, 2025, 11:36 AM EDT - 6 months ago

Axsome: The Alzheimer's Agitation Program For AXS-05

Feb 24, 2025, 1:34 PM EST - 7 months ago

Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs

Feb 20, 2025, 8:15 AM EST - 7 months ago

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering

Feb 18, 2025, 11:12 AM EST - 7 months ago

Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 5:20 PM EST - 7 months ago

Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade

TEVA

Feb 10, 2025, 12:33 PM EST - 7 months ago

Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'

TEVA

Jan 31, 2025, 7:00 AM EST - 8 months ago

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

Jan 30, 2025, 3:55 PM EST - 8 months ago

US FDA approves Axsome Therapeutics' migraine drug

Jan 30, 2025, 3:45 PM EST - 8 months ago

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

Dec 31, 2024, 9:15 AM EST - 9 months ago

Axsome Therapeutics Remains A Buy Despite AXS-05's Mixed Results

Dec 31, 2024, 8:15 AM EST - 9 months ago

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

Dec 30, 2024, 8:13 AM EST - 9 months ago

Axsome Therapeutics, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

TSLA

Dec 30, 2024, 7:15 AM EST - 9 months ago

Axsome's drug for Alzheimer's disease agitation meets main goal in late-stage study

Dec 30, 2024, 7:00 AM EST - 9 months ago

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation

Nov 29, 2024, 10:32 AM EST - 10 months ago

Axsome: Focus On AXS-12 Targeting Narcolepsy, Which Just Released Positive Data

Nov 27, 2024, 1:23 PM EST - 10 months ago

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

Nov 12, 2024, 2:02 PM EST - 11 months ago

Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 1:17 PM EST - 11 months ago

Axsome Therapeutics Q3 Earnings: Stay For The Near Term Catalysts, Then Sell

Nov 8, 2024, 7:00 AM EST - 11 months ago

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

Oct 29, 2024, 7:00 AM EDT - 11 months ago

Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12

Sep 4, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine

Aug 21, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sandoz Inc.

Aug 6, 2024, 3:45 PM EDT - 1 year ago

Axsome's Auvelity: High Hopes Meet Hefty Bills (Rating Downgrade)

Aug 5, 2024, 11:20 AM EDT - 1 year ago

Axsome Therapeutics, Inc. (AXSM) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 7:00 AM EDT - 1 year ago

Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 23, 2024, 4:06 AM EDT - 1 year ago

Axsome Therapeutics: Lots Of Moving Parts

just_another_guy Sep. 17 at 4:02 AM

1 · Reply

highnihilism Sep. 16 at 6:19 PM

IWM: Russell 2000 → $AXSM Axsome Therapeutics $TPC Tutor Perini $TDOC Teladoc Health $LIF Life360 $MVST Microvast

1 · Reply

JDR1983 Sep. 16 at 3:51 PM

$AXSM Added 100 shares.

0 · Reply

jlfromli Sep. 16 at 2:33 PM

$AXSM HT sold This is not good Back to $80S?

1 · Reply

pi22dv7 Sep. 16 at 2:21 PM

$AXSM 20 bucks in 2 weeks, Damn something is really wrong which we are not aware?

1 · Reply

cadbrad1 Sep. 16 at 2:17 PM

$AXSM Been in this for a few years. I’ve seen these kind of drops right before big news and then it rockets up. Hopefully history repeats!

1 · Reply

jozef56 Sep. 16 at 1:47 PM

$AXSM this weak dollar will kill economics on long term ....fed should decrease intrest as max as possible to stimulate investors

0 · Reply

DiligentInvesting Sep. 16 at 1:35 PM

$AXSM should make a drug for bipolarity and treat its stock price with it. Jeez.

0 · Reply

quickaspeter Sep. 16 at 1:27 PM

$AXSM Let’s go!

0 · Reply

Vakeshka Sep. 16 at 12:11 PM

$AXSM Cantor Fitzgerald reaffirms Buy rating with $153 PT.

2 · Reply

OhShutUp Sep. 16 at 3:21 AM

$AXSM $IXHL $JAZZ $LLY So we are only 9 years out? Heck yeah!

0 · Reply

modrica3 Sep. 16 at 2:44 AM

$AXSM $IXHL $JAZZ $LLY its actually great to see ixhl among these big names

1 · Reply

NOOBofNASDAQ Sep. 16 at 2:40 AM

$IXHL $LLY $JAZZ $AXSM https://www.theglobeandmail.com/investing/markets/markets-news/GetNews/34810110/sleep-apnea-market-forecasted-to-surge-in-coming-years-20242034-analysis-by-delveinsight-apnimed-eli-lilly-and-company-incannex-healthcare-axsome-therapeuticsjazz-pharmaceuticals-bioprojet/

1 · Reply

Mike826_1999 Sep. 16 at 2:21 AM

$AXSM Axsome will be participating in the San Diego Psych Congress beginning Wednesday. https://www.hmpglobalevents.com/psych-congress

2 · Reply

200_pips Sep. 15 at 10:56 PM

$AXSM Finally HT decided to sell. I don't blame him. What's point of holding all shares and never sell to enjoy life. Bio is bio and there is always risk, political pressure and uncertainty there. https://axsometherapeuticsinc.gcs-web.com/node/12416/html

2 · Reply

noobzilla Sep. 15 at 6:31 PM

$AXSM 2nd time that I got cash and bought near 130, it starts dropping! Next time I'll announce before buying so folks can start buying puts lol

3 · Reply

Crimson_Phoenix Sep. 15 at 5:00 PM

$AXSM Always the high expectations here at Simply Wall St. Gotta love the optimism, though! https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-axsm/axsome-therapeutics/news/exploring-axsome-therapeutics-axsm-valuation-as-investors-no

0 · Reply

A_Train1 Sep. 15 at 2:23 PM

$AXSM is this a head fake in preparation for potential rate cuts on Wednesday? Or is this the beginning of a significant downtrend and a shift/rotation into technology?

1 · Reply

pi22dv7 Sep. 15 at 2:20 PM

$AXSM Volume is Anemic, bloody algo’s.

0 · Reply

pi22dv7 Sep. 15 at 1:50 PM

$AXSM Big money leaving biotechs, SIGH.

0 · Reply

just_another_guy Sep. 15 at 12:27 AM

$AXSM New TV commercial campaign should increase sales by a significant amount over the next few weeks. Search trend data is already increased so TV commercials are working.

0 · Reply

TrendEdgeLogan Sep. 14 at 7:41 PM

$AXSM $200K unplanned open market buy, increasing director's direct ownership by 3.38% this past week. $XBI $IBB

1 · Reply

Market Cap	5.91B
Revenue (ttm)	385.69M
Net Income (ttm)	-287.22M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-74.47%
Debt to Equity Ratio	1.61

Volume	735,800
Avg Vol	616,064
Day's Range	N/A - N/A
Shares Out	49.90M
Stochastic %K	5%
Beta	0.54
Analysts	Strong Sell
Price Target	$175.50